IP Library Granted Patent US 9,879,045
Granted Patent B2
US 9,879,045 · App. 14/892,539 · Granted Jan 30, 2018

Processes for the preparation of dehydroepiandrosterone and its intermediates

Inventors: Anna Fryszkowska (Cambridge, GB); Michael Siegfried Quirmbach (Basel, CH); Srikanth Sarat Chandra Gorantla (Hyderabad, IN); Sanjay Reddy Alieti (Hyderabad, IN); Srinivas Reddy Poreddy (Nalgonda, IN); Naresh Kumar Reddy Dinne (Mahaboob Nagsar, IN); Upadhya Timmanna (Hyderabad, IN); Vilas Dahanukar (Hyderabad, IN)
Assignee: DR. REDDY'S LABORATORIES LIMITED
C07J1/0011C12P33/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,879,045
App. No.
14/892,539
Granted
Jan 30, 2018
Kind
B2
Abstract

The present application relates to a regioselective and stereoselective processes for the preparation of dehydroepi-androsterone (DHEA) and processes for its intermediates.

Claims (14)

1. A process for preparing 3β-hydroxyandrost-5-en-17-one of formula (I)

comprising reducing 3-oxo group of Δ 5 -androstene-3,17-dione of formula (II)

using a ketoreductase enzyme having SEQ ID NO:1.

2. A process for preparing the compound of formula (III)

comprising:

acetylating the compound of formula (I), wherein the compound of formula (I) is prepared according to claim 1 ,

3. A process for the preparing compound of formula (III)

comprising the steps of:

a) isomerizing Δ 4 -androstene-3,17-dione of formula (IV)

to give Δ 5 -androstene-3,17-dione of formula (II);

b) regioselectively and stereoselectively reducing the 3-oxo group of Δ 5 -androstene-3,17-dione of formula (II) using a ketoreductase enzyme, wherein the compound of formula (II) is prepared according to claim 1 to obtain 3β-hydroxyandrost-5-en-17-one of formula (I); and

c) acetvlatinq the compound of formula (I) to obtain the compound of formula (III).

4. The process of claim 1 , wherein compound of formula (I) is converted to Abiraterone acetate.

5. The process of claim 1 , wherein the compound of formula (I) is converted to DHEA Enanthate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2017
From: FRYSZKOWSKA, ANNA; QUIRMBACH, MICHAEL SIEGFRIED; GORANTLA, SRIKANTH SARAT CHANDRA; ALIETI, SANJAY REDDY; POREDDY, SRINIVAS REDDY; DINNE, NARESH KUMAR REDDY; TIMMANNA, UPADHYA; DAHANUKAR, VILAS
To: DR. REDDY'S LABORATORIES LIMITED
Reel/Frame 044332/0389 →
Priority Claims (1)
IN 2214/CHE/2013 · May 21, 2013 · national
Continuity (1)
Related Publication 20160122382A1 · May 5, 2016